APP and amyloidosis: Interestingly, insulin administered by intranasal improved cognitive dysfunction and insulin signaling, reduced amyloid-β (Aβ) production and amyloid plaque burden, and increased neurogenesis in 4-month-old APP/PS1 mice showing early Alzheimer's disease (AD) pathologies [10].